Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Thrombosis Research

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2018.01.044PMID 29407620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Point-of-Care Testing of Coagulation in Patients Treated With Non–Vitamin K Antagonist Oral Anticoagulants

  2015cited by this paper
• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

  2015cited by this paper
• Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests

  2014cited by this paper
• Performance of coagulation tests in patients on therapeutic doses of rivaroxaban

  2014cited by this paper
• Measurement of non‐Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology

  2014cited by this paper
• Point-of-Care Coagulation Testing for Assessment of the Pharmacodynamic Anticoagulant Effect of Direct Oral Anticoagulant

  2014cited by this paper
• The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

  2014cited by this paper
• Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban

  2013cited by this paper
• The laboratory and the direct oral anticoagulants.

  2013cited by this paper
• Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature

  2012cited by this paper
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• Interpretation of point-of-care INR results in patients treated with dabigatran.

  2012cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

  2011cited by this paper
• Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor

  2010cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper

• Real-world national trends and influencing factors preference of non-vitamin K antagonist oral anticoagulants in China

  2023cites this paper
• Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study

  2022cites this paper
• Current Challenges and Future Trends of Enzymatic Paper-Based Point-of-Care Testing for Diabetes Mellitus Type 2

  2021cites this paper
• Diagnostic Modalities in Critical Care: Point-of-Care Approach

  2021cites this paper
• Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data

  2021cites this paper
• Toxicology Testing at the Point of Contact

  2020cites this paper
• An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants

  2020influential citation
• Detection platforms for point-of-care testing based on colorimetric, luminescent and magnetic assays: A review.

  2019cites this paper
• Benefits and Pitfalls of Point-of-Care Coagulation Testing for Anticoagulation Management: An ACLPS Critical Review

  2018cites this paper
• What's New in Point-of-Care Testing?

  2006cites this paper